Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
CT 2584
Known as:
CT-2584
, CT2584
, CT2584 HMS
A substance that is being studied in the treatment of cancer. It may prevent the growth of blood vessels from surrounding tissue into a solid tumor.
National Institutes of Health
Create Alert
Related topics
Related topics
2 relations
Narrower (1)
Apra
Broader (1)
Xanthines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
CT-2584 (Cell Therapeutics).
R. Bonfil
Current opinion in investigational drugs
2001
Corpus ID: 22139733
CT-2584, an anticancer agent that inhibits phospholipid signaling, is under development by Cell Therapeutics Inc (CTI) as a…
Expand
2001
2001
CT-2584 (Cell Therapeutics).
Bonfil Rd
2001
Corpus ID: 81498599
2000
2000
Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines.
R. Finney
,
E. Nudelman
,
+7 authors
R. Lewis
Cancer research
2000
Corpus ID: 2885334
De novo production of phosphatidic acid (PA) in tumor cells is required for phospholipid biosynthesis and growth of tumor cells…
Expand
2000
2000
Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours
S. Cheeseman
,
M. Brannan
,
+5 authors
M. Ranson
British Journal of Cancer
2000
Corpus ID: 15449638
CT-2584 HMS, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine-hydrogen methanesulphonate, is a modulator of…
Expand
1999
1999
Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatography assay for the novel antitumour agent CT2584 in human plasma.
P. Khan
,
S. Abbas
,
S. Cheeseman
,
M. Ranson
,
A. McGown
Journal of chromatography. B, Biomedical sciences…
1999
Corpus ID: 33532491
A HPLC assay and solid-phase extraction technique from human plasma has been developed and validated for the novel anticancer…
Expand
Highly Cited
1997
Highly Cited
1997
Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses.
H. Shau
,
A. Kim
,
+5 authors
D. Paglia
Free radical biology & medicine
1997
Corpus ID: 41336614
Natural killer-enhancing factor (NKEF) was identified and cloned on the basis of its ability to increase NK cytotoxicity. Two…
Expand
1997
1997
Effect of a xanthine analog on human hepatocellular carcinoma cells (Alexander) in culture and in xenografts in SCID mice
L. Marucci
,
L. Varticovski
,
I. Arias
Hepatology
1997
Corpus ID: 19215709
Hepatocellular carcinoma (HCC) frequently overexpresses the MDR1 gene and is resistant to drugs transported by the multidrug…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE